different glp-1 medications New Guidelines for Type 2 Diabetes in 2025 Indications for GLP-1/GIP RA Summary

D-carnitine is a competitive inhibitor of L-carnitine

On the other hand, GLP-1/GIP tirzepatide differs because it is a dual medication

Muta Y, Kobayashi K, Toyoda M, et al

This dual action appears to amplify appetite suppression and metabolic regulation beyond what GLP-1 activation alone produces, which is why clinical trials consistently show greater average weight loss with tirzepatide

Study limitations Although pomegranate extract effects on TMAO production were observed in female participants of premenopausal age and male participants, this remains a proof-of-concept study with a small population and smaller subgroups, including only three female participants in the Older (postmenopausal age) group and three in the Younger (premenopausal age) group